We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 23.50 | 1.38% | 1,728.50 | 1,727.50 | 1,728.50 | 1,729.50 | 1,695.50 | 1,705.00 | 6,275,020 | 16:35:24 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.42 | 71.04B |
From May 2022 to May 2024
By Joe Hoppe
GSK PLC said Tuesday that its Nucala add-on maintenance treatment for adults with severe eosinophilic asthma, or SEA, has been accepted for a new drug application in China.
The pharmaceutical giant said that if the China National Medical Products Administration approves the drug for use treating SEA, it would be the first targeted treatment in China for adults and adolescents with the condition.
The application is based on positive data from a Phase 3 trial program among Chinese patients and the global SEA development program, which included three key clinical trials that established the efficacy and safety profile of the drug.
Asthma affects an estimated 46 million people in China, with 6% experiencing severe asthma, and patients with SEA have an increased risk of exacerbations needing hospitalization or an increased likelihood of a potentially fatal attack.
Nucala is currently approved in China for use in adults with eosinophilic granulomatosis with polyangiitis, and was approved in 2015 for SEA treatment in the U.S. It has since been approved in the European Union and more than 25 other markets as an SEA treatment.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
March 14, 2023 03:32 ET (07:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
